# Psychiatry Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zelda Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET004-SYN-TD
- Date: 1930-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desiree Langford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Margot Ellery, MD

## Reason for consultation

First episode of psychosis with marked manic and depressive symptoms in a 29-year-old dancer and writer, twelve days after discharge from a first psychiatric admission, on risperidone 2 mg at bedtime. Please review the provisional diagnosis and how to settle it, advise on a mood stabilizer to prevent another episode in a woman who could become pregnant, advise on the antipsychotic given a raised prolactin and absent periods, and enroll her in coordinated specialty care. **S**

## History

Ms. Fitzgerald, a 29-year-old dancer and writer, is seen at the request of Dr. Ellery four weeks after risperidone was started in hospital. Before the admission she had weeks of very little sleep without tiredness, rapid speech, racing thoughts, grand plans to join a professional company within the year, and training for most of each day; near the end she heard a voice commenting on her dancing and became convinced that her instructors were watching and testing her through signals. She is not sure which came first. Since discharge she has been low and tired but less tearful this week, sleeps nine or ten hours, and has no psychotic or manic symptoms. She has had no previous episodes of depression or mania. She drinks a little at weekends and uses no drugs. Her periods stopped months before the admission. She eats small portions to stay light and felt guilty on rest days, but she does not binge or purge. She has no thoughts of suicide or self-harm. Her fear is that medicines will make her heavy and end her dancing. **S**

## Examination

| System | Finding |
|---|---|
| General | Slim and well; blood pressure 106/66, pulse 76; waist 66 cm |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Mental status | Quiet and cooperative; reactive affect; organized; no hallucinations or delusions elicited; no manic features; no suicidal thoughts; insight good |

BP 106/66 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 51 kg; BMI 18.7 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Ellery's intake note, safety assessment, and safety plan. Intake results: creatinine 0.72 mg/dL, eGFR 116; sodium 139 and potassium 4.0 mmol/L; calcium 9.4 mg/dL; TSH 2.1 mIU/L; prolactin 62 ng/mL; A1c 5.0%; total cholesterol 168, LDL 90, HDL 64, triglycerides 70 mg/dL; hemoglobin 12.6 g/dL. PHQ-9 11 at intake and 9 today; AUDIT-C 2; SCOFF 1 of 5. Urine pregnancy test negative today. Weight 51.0 kg, BMI 18.7. PHQ-9: 9. All results are synthetic.

## Assessment

1. **First episode of psychosis with marked mood symptoms, provisional diagnosis** (F29). The full manic syndrome before admission and the depressive phase after it make bipolar I disorder with psychotic features the most likely diagnosis. Schizoaffective disorder would require psychotic symptoms for two weeks or more without mood symptoms, and schizophrenia would require psychosis outside mood episodes and usually a decline in function; neither is shown, but the order of symptoms is not yet established. A clearer history, from her own notes or journal and, with her consent, from her roommate, together with the course over the next months, should settle it; the diagnosis should be reviewed at about three months and again if psychosis ever occurs without mood symptoms. Lithium is the first choice for preventing further episodes. Valproate should not be used in a woman who could become pregnant because of its risks of birth defects and effects on a child's development. Lithium carries a small added risk of heart defects with exposure early in pregnancy, which is manageable with reliable contraception and planned pregnancy. **S**
2. **Secondary amenorrhea** (N91.1). The periods stopped before risperidone, which points to low energy availability from heavy training at a low weight; risperidone's prolactin rise may now be prolonging it. Changing the antipsychotic and adding lithium at the same time would make side effects hard to read, so lithium should be started first and the antipsychotic switched if prolactin stays high and the periods do not return. **S**

## Recommendations

1. Start lithium carbonate 300 mg twice daily now; check a 12-hour trough level 5 to 7 days after starting and after any change, aiming for 0.6 to 0.8 mmol/L.
2. Creatinine and eGFR every two to three months for six months, TSH once or twice in the first six months, calcium yearly, then lithium level every three to six months.
3. Teach and write down lithium sick-day rules: stop it during vomiting, diarrhea, or dehydration and call; avoid anti-inflammatory painkillers.
4. Do not use valproate. Use reliable contraception, preferably a long-acting method, and plan any pregnancy with psychiatry.
5. Continue risperidone for now; if prolactin is still raised and her periods have not returned at the next check, switch to aripiprazole, which spares prolactin and has a lower metabolic risk.
6. Monitor weight at every visit for six months after starting or changing the antipsychotic, blood pressure, fasting glucose or A1c and lipids at 12 weeks to four months and then yearly, and the AIMS every six months.
7. Gather a clearer history of the episode, with her consent, and review the diagnosis at about three months.
8. Arrange a sports dietitian and a graded return to dance with food matched to the training load; watch training hours and sleep as early warning signs.
9. Enroll her in coordinated specialty care: care coordination, therapy with psychoeducation about bipolar disorder, education for the people she chooses, support to return to dance and writing, and a peer specialist.
10. Continue lithium for the long term after a first manic episode with psychosis; consider a slow taper of the antipsychotic after six months or more of remission, with a written relapse plan.

## Strengths and supports

- Supports: her friend and roommate, her dance class, and the coordinated specialty care team; writing and painting are her strongest sources of purpose. She decides who is told about her health **S**

## Communication

Discussed with Dr. Ellery, who sees her the same day. The plan was explained to Ms. Fitzgerald, who agreed to start lithium and to join the coordinated specialty care program; she decides who else receives this note. **S**

## Follow-up

Psychiatry review through the coordinated specialty care team at about three months to review the diagnosis, and after six months of remission about the antipsychotic; Dr. Ellery continues prescribing and monitoring. **S**

## Guideline basis

- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023), Focus (American Psychiatric Publishing)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
